SMND-309

• UNSPSC Description:

  SMND-309 is a metabolite of salvianolic acid B, and exhibits neuroprotective effects in cultured neurons and in permanent middle cerebral artery occlusion rats[1][2].

• Target Antigen:

  Drug Metabolite

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/SMND-309.html

• Purity:

  96.81

• Solubility:

  DMSO : ≥ 3.7 mg/mL

• Smiles:

  OC1=C(C(/C=C/C(O)=O)=CC=C1O)/C(C(O)=O)=C\C2=CC(O)=C(C=C2)O

• Molecular Weight:

  358.30

• References & Citations:

  [1]Hou J, Tian J, Jiang W, Gao Y, Fu F. Therapeutic effects of SMND-309, a new metabolite of salvianolic acid B, on experimental liver fibrosis. Eur J Pharmacol. 2011 Jan 10;650(1):390-5.|[2]Yang J, Zhang G, Tian J, Li C, Jiang W, Xing Y, Zhu H, Hou J, Xu H, Wu J. Cardioprotective effect of SMND-309, a novel derivate of salvianolic acid B on acute myocardial infarction in rats. Basic Clin Pharmacol Toxicol. 2010 Apr;106(4):317-23.|[3]Wang Y, Zhang J, Han M, et al. SMND-309 promotes neuron survival through the activation of the PI3K/Akt/CREB-signalling pathway. Pharm Biol. 2016;54(10):1982-1990.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1065559-56-9